Back to results
US 11,844,833 B2Granted
Expression system for expressing herpesvirus glycoprotein complexes
AssigneeCity of Hope
InventorsFelix Wussow, Don J. Diamond
Life of this patent
Estimating the term…
Abstract
An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.
Claims21
A pharmaceutical composition comprising:
- (i) one or more vectors, each vector comprising one or more expression cassette(s), each expression cassette comprising:
- a single promoter;
- two or more nucleic acid sequences that encode two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the expression cassette, form a herpesvirus glycoprotein complex that is functional and effectively elicits neutralizing antibody responses, and wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7);
- one or more 2A peptide signal sequences that mediate ribosomal skipping or one or more internal ribosomal entry sites between each of the two or more nucleic acid sequences;
- wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are simultaneously expressed by the expression cassette;
- wherein the one or more vectors is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector;
- and
- (ii) a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof.
5 more elements
A pharmaceutical composition comprising:
- (i) a first vector comprising a first expression cassette, the first expression cassette comprising:
- a first promoter, two or more nucleic acid sequences that encode two or more amino acids herpesvirus glycoprotein complex subunits or antigenic fragments thereof, and
- one or more 2A signal sequences between each of the two or more nucleic acid sequences,
- wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the first expression cassette, form a herpesvirus glycoprotein complex;
- wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7);
- and
- wherein the first vector is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector;
- and
- (ii) a second vector comprising a second expression cassette, the second expression cassette comprising:
- a second promoter, two or more nucleic acid sequences that encode two or more amino acids herpesvirus glycoprotein complex subunits or antigenic fragments thereof, and
- one or more 2A signal sequences between each of the two or more nucleic acid sequences, wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the second expression cassette, form a herpesvirus glycoprotein complex;
- wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7);
- and
- wherein the second vector is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector;
- wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof of the first and second vectors are simultaneously expressed;
- and
- (iii) a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof.
14 more elements
Dependencies are inferred from the claim text.